Manufacturer Name	NDC	Name of Prescription Drug	Strength	Pack Size/Volu me	WAC (as of date of commercial availability)	Date of Commercial Availability	Estimated volume of patients who may be prescribed drug
Pharmaka Generics	82644008760 Tet	racycline HCL 250mg	250mg	60	\$2,500.00	3/6/2024	Depends on the prescribers, but we anticipate that about 2,000 to 4,000 patients will be prescribed per month
Pharmaka Generics	82644087060 Tet	racycline HCL 500mg	500mg	60	\$2,500.00	3/6/2024	Depends on the prescribers, but we anticipate that about 2,000 to 4,000 patients will be prescribed per month

Breakthrough therapy designation? (Y/N)	Priority Review? (Y/N)	Date and price of acquisition if the drug was not developed by the manufacturer else N/A	A description of the marketing and pricing plans used in the launch of the new drug		
N	N	N/A	Provide an alternative to prescribers for Antibotics for Tetracycline by introducing a tablet in the market.  Spending on the promotion of the drug to physicians or other health professionals, such as professional detailing, or other promotional activities.		
N	N	N/A	Provide an alternative to prescribers for Antibotics for Tetracycline by introducing a tablet in the market.  Spending on the promotion of the drug to physicians or other health professionals, such as professional detailing, or other promotional activities.		